louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02020668: Efficacy of Physiotherapy on the Health and Quality of Life of the Rheumatic Patient
Official title: Phase II Study of Physiotherapy in Rheumatoid Arthritis: Randomized Single Blind Wait-list Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Rheumatic Arthritis
Keywords: Pain
Functional capacity
Quality of Life
Lead sponsor: Macmillan Research Group UK
Sponsor class: INDUSTRY
Collaborators: name: NMP Medical Research Institute
name: Warwick Research Services
First posted: 2013-12-25
Enrollment: 82
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Despite leading cause of morbidity, treatment strategies for Rheumatic diseases are geared almost exclusively toward medical-pharmacological area away from offering the patient the possibility of an interdisciplinary approach to their disease.

Present study test whether treatment of physiotherapy reduces stiffness and pain inherent in rheumatic disease and improve their quality of life related to health.


Eligibility criteria: Inclusion Criteria:

* Patients older than 18 years
* History of Rheumatoid Arthritis (RA) symptoms for less than 7 years
* Had RA by American College of Rheumatology (ACR) criteria
* ACR functional RA class I, II or III
* Hemoglobin more than 8g/dL without evidence of active bleeding
* Positive for rheumatoid factor (RF) or anti cyclic citrullinated protein
* standard conventional medicine were allowed within the approved dosage regimen

Exclusion Criteria:

* connective tissue disease
* any other alternative or complementary medicine with in last 3 months.
* corticosteroid, disease modifying medicines
* Poorly controlled diabetes, hypertension, hepatitis, cardiac disease, liver diseases, carcinoma, drug abuse

Primary outcomes:
measure: Pain
timeFrame: Change from baseline in Numerical Scale Downie at 16 weeks
Secondary outcomes:
measure: Quality of Life
timeFrame: Change from Baseline in Short Form (SF) 36 at 16 weeks
Other outcomes:
measure: Functional capacity
timeFrame: Change from baseline in Barthel Index at 16 weeks
Locations:
city: Sikar
country: India
facility: Life Line Hospital
state: Rajasthan
Study officials:
affiliation: Macmillan Research Group
name: Neha Sharma, PhD
role: STUDY_DIRECTOR
affiliation: Life Line Hospital, Sikar, India
name: Om Prakash Sharma, MBBS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03646968: Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study
Official title: Phase II Study to Evaluate the Effectiveness and Safety of Anlotinib Combined With Docetaxel in Progress After First Line Standard Cheomotherapy in Advanced Non-driver Mutation Non- Squamous Non-small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Non-Squamous Non Small Cell Lung Cancer
Keywords: Anlotinib Combined With Docetaxel
Lead sponsor: Hunan Province Tumor Hospital
Sponsor class: OTHER
First posted: 2018-08-24
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the Effectiveness and Safety of Anlotinib combined with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer

Detailed description: The purpose of this study is to evaluate the Effectiveness and Safety of Anlotinib combined with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer .According to the result of TAX317,the ORR of second line standard chemotherapy was 5- 8%. We expect the ORR was 20%. Using PASS11, we calculated the sample size of this study was 39 , according to 10% censoring,the expected sample size is 43.

Eligibility criteria: Inclusion Criteria:

* 18，Pathologically proven Non squamous non small cell lung cancer

  * No-drive gene mutaion (EGFR、ALK、ROS1） by NGS
  * Progress after second line
  * PS score 0-2

Exclusion Criteria:

* Patients received second line treatment
* Patients received treatment of Anlotinib or Docetaxel
* Patients with contraindication of chemotherapy
* Pregnant or breast feeding women

Primary outcomes:
measure: ORR
timeFrame: may 2018- may 2019 (1 year)
Secondary outcomes:
measure: PFS
timeFrame: may 2018- may 2019 (1 year)
measure: OS
timeFrame: may 2018- may 2019 (1 year)
Other outcomes:
Locations:
city: Changsha
country: China
facility: Hunan Cancer Hospital
state: Hunan
Study officials:
affiliation: Hunan Cancer Hospital
name: Yongchang Zhang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03234868: Benefit of the Digital Workflow for Screw-retained Single Implant Restorations
Official title: Benefit of the Digital Workflow for Screw-retained Single Implant Restorations
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Tooth Loss
Lead sponsor: University of Liege
Sponsor class: OTHER
First posted: 2017-07-31
Enrollment: 34
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this research project is emphasize the benefit of the digital workflow compared to conventional impressions and crown processing with standard la procedures. The objectives of the present study are to measure and compare the global cost, the time spent in the dental chair and in the lab and the fit of both digital and conventional workflow. Additionally, patient centered outcomes will be recorded.


Eligibility criteria: Inclusion Criteria:

* Subject must have voluntarily signed the informed consent form before any study related action
* Age: 18 with one or more missing teeth in the maxillary area, seeking for implant therapy.
* Men/Women
* In good systemic health (ASA I/ II)
* Present with no contra indication against oral surgical interventions
* Patients required replacement of a single missing tooth. The tooth at the implant site(s) must have been extracted or lost at least 12 weeks before the date of implantation.
* At least 10 mm of bone in the vertical dimension
* At least 6 mm of bone in the bucco-lingual dimension.
* No need for bone augmentation procedure in any of the dimensions
* Full mouth plaque score (FMPI) lower or equal than 25%

Exclusion Criteria:

* Autoimmune disease require medical treatment
* Medical conditions requiring prolonged use of steroids
* Use of Bisphosphonate intravenously or more then
* Infection (local or systemic) - patient with gingivitis or active local infection will undergo a medical treatment prior to his entrance to the study, each individual will be evaluated prior to study procedure for suitability, in case of systemic infection the evaluation will be based on medical anamneses, and if necessary will be referred to relevant medical tests.
* Current pregnancy or breastfeeding women
* Alcoholism or chronically drug abuse
* Immunocompromised patients
* Uncontrolled Diabetes
* Smokers
* Prisoners

Primary outcomes:
measure: Fit of the crowns
timeFrame: 1 year
Secondary outcomes:
measure: Time consumption at the dental chair
timeFrame: 1 year
measure: Time consumption in the lab
timeFrame: 1 year
measure: Global cost
timeFrame: 1 year
measure: Esthetical aspect
timeFrame: 1 year
measure: Patient centered outcomes
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06211868: Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study
Official title: Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cardiovascular Diseases
Metabolic Syndrome
Non-Alcoholic Fatty Liver Disease
Lead sponsor: National University Hospital, Singapore
Sponsor class: OTHER
Collaborators: name: National University of Singapore
First posted: 2024-01-18
Enrollment: 3000
Sex: ALL
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: South-East Asian population aged 40-70 years with no prior manifest atherosclerotic cardiovascular disease (ACSVD).

Brief summary: Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as clinicians across primary and tertiary care to study the immune, lipid and metabolic drivers of early cardiovascular disease. RESET incorporates a nested randomised controlled trials (RCT) to test the use of a combined digital wearable and AI-human symbiotic lifestyle intervention to halt or reverse the progression of early disease.


Eligibility criteria: Inclusion Criteria:

* 40-70 years old
* ASCVD (atherosclerotic cardiovascular disease) score of 5% and higher

Exclusion Criteria:

* Previous major cardiovascular disease (myocardial infarction, heart failure, ischemic stroke)
* Limited life expectancy
* Other ongoing unstable medical conditions
* Pregnant women

Primary outcomes:
measure: Major adverse cardiovascular event
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: NUS
Study officials:
References:
Clinical trial NCT01820468: Adapting a Model for Veterans on a Psychiatric Inpatient Unit
Official title: Adapting a Critical Time Intervention Model for Veterans on a Psychiatric Inpatient Unit
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Conditions: Serious Mental Illness
Lead sponsor: VA Connecticut Healthcare System
Sponsor class: FED
First posted: 2013-03-28
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomized controlled study tests an adapted critical time intervention model for veterans discharged from a psychiatric inpatient unit. It is hypothesized that veterans on the inpatient unit who are assigned to such a community-based team will have shorter lengths of inpatient stay and better mental health. There have been few developments of community-based models of care in the post-deinstitutionalization era of short inpatient stays and the results of the study may inform how inpatient stays can be further reduced.


Eligibility criteria: Inclusion Criteria:

1. Admitted to the psychiatric inpatient unit for at least 4 days
2. Willing to participate in community-based treatment

Exclusion Criteria:

1. Actively suicidal or homicidal
2. Dementia
3. Drug or alcohol detoxification
4. Physician emergency certificate

Primary outcomes:
measure: Length of inpatient stay
timeFrame: 1 month follow-up
Secondary outcomes:
measure: Mental health functioning
timeFrame: 1 month follow up
Other outcomes:
Locations:
Study officials:
affiliation: VA Connecticut Healthcare System
name: Jack Tsai, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01976468: Metastases of Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients. The "SCOPE-ITSCC Metastases Study"
Official title: Metastases of Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients. The "SCOPE-ITSCC Metastases Study"
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Squamous Cell Carcinoma
Lead sponsor: University of Zurich
Sponsor class: OTHER
Collaborators: name: Leiden University Medical Center
First posted: 2013-11-05
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: organ transplant recipients

Brief summary: The investigators hypothesize that a low number of SCC in OTR will metastasize.

Detailed description: In a large international multicenter prospective observational study a total number of 1000 OTR (organ transplant recipients) with a histologically proven cutaneous SCC (squamous cell carcinoma) will be included in 10 centers and followed during 2 years to establish the cumulative incidence of metastases in OTR with cutaneous SCC.

Eligibility criteria: Inclusion criteria:

* Organ-transplant recipients (OTR).
* Histologically proven cutaneous invasive SCC at time of inclusion

Exclusion criteria:

* Lack of consent.
* History of metastases of cutaneous SCC

Primary outcomes:
measure: SCC metastasis detection
timeFrame: two years
Secondary outcomes:
Other outcomes:
Locations:
city: Leiden
country: Netherlands
facility: Leiden University Medical Center
city: Zurich
country: Switzerland
facility: University Hospital Zurich, Division of Dermatology
state: ZH
Study officials:
affiliation: University Hospital Zurich, Division of Dermatology
name: Günther Hofbauer, Prof MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Leiden University Medical Center
name: Jan Nico Bouwes Bavinck
role: STUDY_CHAIR
affiliation: Leiden University Medical Center
name: Roel Genders, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00434668: Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer
Official title: Randomized Phase II Study Evaluating The Tolerability Of Adjuvant Docetaxel-based Chemotherapy For Completely Resected Stage IB-II Non-Small Cell Lung Cancer (NSCLC): Toledo Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Non-small Cell Lung Cancer
Keywords: Non-Small Cell Lung Cancer
NSCLC
Adjuvant chemotherapy for completely resected NSCLC
Lead sponsor: University Hospital, Antwerp
Sponsor class: OTHER
Collaborators: name: Universiteit Antwerpen
name: Sanofi
First posted: 2007-02-13
Enrollment: 99
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate the tolerability (in terms of drug delivery and toxicity) of four cycles of adjuvant docetaxel plus cisplatin in patients with completely resected stage IB-II Non-Small Cell Lung Cancer. To avoid a selection bias, eligible patients will be randomised to receive cisplatin/docetaxel or cisplatin/vinorelbine.


Eligibility criteria: Inclusion Criteria:

* completely resected pathological stage IB or II NSCLC
* adequate haematological, renal and liver function and condition

Exclusion Criteria:

* previous chemo or radiotherapy for NSCLC
* bronchoalveolar cell subtype
* second active primary malignancy or serious concomitant medical disease
* difficulties with adequate follow-up

Primary outcomes:
measure: Success of delivery treatment; data collected during chemotherapy treatment
measure: Toxicity (occurrence of any grade 4 toxicity); data collected at the end of each cycle
Secondary outcomes:
measure: Overall toxicity
measure: Progression free survival and overall survival
Other outcomes:
Locations:
city: Antwerpen
country: Belgium
facility: ZNA Middelheim
state: Antwerp
city: Edegem
country: Belgium
facility: University Hospital Antwerp
state: Antwerp
city: Wilrijk
country: Belgium
facility: St Augustinus ziekenhuis
state: Antwerp
Study officials:
affiliation: Universiteit Antwerpen
name: Paul R. Germonpre, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05192668: The Setting and Effect Evaluation of QT in NICU
Official title: The Setting and Effect Evaluation of Quiet Time in Neonatal Intensive Care Unit
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Very Low Birth Weight Infant
Keywords: Quiet Time
Weight
Lead sponsor: Children's Hospital of Fudan University
Sponsor class: OTHER
First posted: 2022-01-14
Enrollment: 124
Sex: ALL
Maximum age (years): 1
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: In order to create a better environment for growth and development for very low birth weight infants(VLBWIs), investigators introduce quiet time, which is an intervention method that reduces environmental noise in the ward and centralizes medical and nursing operations. By analyzing the weight gain of VLBWIs in the intervention group and the control group during hospitalization, the effect of setting a quiet time in the NICU on improving the growth and development of VLBWIs is evaluated.


Eligibility criteria: Inclusion Criteria:

* Birth weight \<1500g;
* Admit within 24 hours of birth;
* The guardian signs the informed consent.

Exclusion Criteria:

* Newborn with severe congenital malformations or various chromosomal diseases, genetic metabolic diseases, severe neurological diseases;
* Newborn who do not achieve discharge or death at the end of the study period.

Primary outcomes:
measure: Mean weekly gain in weight of VLBWIs
timeFrame: From the day the VLBWI admitted to the day VLBWI discharged, about two months.
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Children's Hospital of Fudan University
state: Shanghai
Study officials:
References:
Clinical trial NCT05656768: Sleep and Circadian Contributions to Nighttime Blood Pressure
Official title: Sleep and Circadian Contributions to Nighttime Blood Pressure
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Sleep
Circadian Rhythm
Blood Pressure
Hypertension
Keywords: sleep
circadian rhythm
circadian misalignment
nocturnal hypertension
non-dipping blood pressure
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
First posted: 2022-12-19
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Broadly, this study (SCN-BP) seeks to examine sleep and circadian factors that contribute to blood pressure levels at night.

Detailed description: SCN-BP is imbedded in a parent grant titled "Improving the Detection of Hypertension (IDH-MEGA)" and examines a variety of sleep (e.g., sleep duration, timing, and the presence of sleep disorder) and circadian factors in Aims 1 and 2. In Aim 3, the investigators will conduct a 30-hour constant routine protocol to directly examine endogenous circadian and blood pressure rhythms.

Eligibility criteria: Inclusion Criteria:

* Participant in the parent grant (IDH-MEGA)

Exclusion Criteria:

-

Primary outcomes:
measure: Change in Melatonin
timeFrame: Hourly samples obtained over 30 hours
measure: Change in Core body temperature
timeFrame: Continuous measurements over 30 hours
Secondary outcomes:
measure: Change in Blood pressure
timeFrame: Measurements obtained every 30 minutes over 30 hours
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
Study officials:
affiliation: University of Alabama at Birmingham
name: Stephen J Thomas, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00599768: Development and Validation for Taiwan Version ID Pain Questionnaire (ID Pain-T) and DN4 Questionnaire.
Official title: Development and Validation for Taiwan Version ID Pain Questionnaire (ID Pain-T) and DN4 Questionnaire.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neuralgia
Nerve Pain
Neuropathic Pain
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2008-01-24
Enrollment: 325
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients of non-headache pain for more than 30 days and those whose age is more than 18 years old

Brief summary: This prospective cohort and multi-site study aims to develop Taiwan version (ID Pain-T) based on the original versions of ID Pain and also DN4, and validate both ID Pain-T and DN4 applied in Taiwanese subjects at the clinical setting.


Eligibility criteria: Inclusion Criteria:

* Subjects without headache pain over 30 days and at least 18 years old who will visit the clinic, inclusive of male and female.
* Subjects who are able to complete the ID Pain-T Questionnaire.

Exclusion Criteria:

* Subjects who are illiterate or unable to complete questionnaire.
* Subjects who are currently participating in another study or have participated in another pain study within one month of study entry.
* Subjects with low back pain are unable to participate in this study; as the sciatica caused by the piriformis (exclusive of the other types of sciatic pain), lumbago, unclear identification in nerve injury (e.g. complex regional pain syndrome type I) or mixed origin (e.g. cancer pain).

Primary outcomes:
measure: Determine the optimal cut-off score of ID Pain-T Questionnaire for screening of neuropathic pain
timeFrame: end of study
Secondary outcomes:
measure: Evaluate the predictive power of ID Pain-T Questionnaire for diagnosis of neuropathic pain
timeFrame: end of study
measure: Develop and evaluate validity of a short form diagnostic tool based on DN4 structure
timeFrame: end of study
Other outcomes:
Locations:
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT04805268: A Single Case Study of Hypermetabolism
Official title: A Single Case Study of Hypermetabolism
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypermetabolism Due to Defect in Mitochondria
Luft Disease
Lead sponsor: The Hospital for Sick Children
Sponsor class: OTHER
First posted: 2021-03-18
Enrollment: 1
Sex: ALL
Minimum age (years): 9
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: In the Metabolic Disorder clinic at The Hospital for Sick Children, the investigators identified a male, proband with possible Luft's disease. The investigators hypothesize that Luft's disease is caused by excess or dysregulation of brown/beige fat tissue.

To address the hypothesis, the investigators would like to assess brown fat distribution and activity in this subject.

Detailed description: The subject will undergo a fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F FDG PET/CT) at the Diagnostic Imaging unit of The Hospital for Sick Children.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of hypermetabolism, possible Luft's disease.

Exclusion Criteria:

* None

Primary outcomes:
measure: Brown/beige fat tissue distribution and activity. Measurement tool- 18F FDG PET/CT (fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography)
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: The Hospital for Sick Children
Study officials:
affiliation: The Hospital for Sick Children
name: Andreas Schulze, MD
role: PRINCIPAL_INVESTIGATOR
References: